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Telangiectatic Mastocytosis Treated with Intense Pulsed Light
Kelly Quinn, DO and Stephen M. Purcell, DO
Lehigh Valley Health Network, Allentown, PA

Case Presentation
Patient: 42 year-old Hispanic female.
History of Present Illness: Our patient presents
with a rash and persistent redness of the face. The rash has been
present since childhood and is described as being located all over.
It is occasionally associated with pruritus and “hives.” She denies
previous treatment and history of anaphylactic reaction.
Medical/Surgical History: Diabetes mellitus type
II, hypertension, hyperlipidemia, anemia, anxiety, depression,
gastroesophageal reflux disease, cholecystectomy
Current Medications: Insulin, liraglutide, metformin,
simvastatin, lisinopril, aspirin, methylphenidate, monteleukast,
omeprazole, clonazepam, trazodone

Fig. 1

Figure 1: Discrete and coalescent telangiectasias prior to
initiation of intense pulsed light (IPL) treatment.

Laboratory Data: (10/27/2015) RDW 17.2% (12-16%),
lactate dehydrogenase 94 (100-250 U/L), tryptase 129 ug/L (<10.9
ug/L), (11/02/2015): blood- positive for KIT (D816v) point mutation
by PCR; remainder CBC, CMP, B-2 microglobulin, IgA, IgG, IgM WNL
Physical Examination: Scattered 0.5-1.5cm thin,
red-brown papules and plaques on the trunk, arms, and legs with
telangiectasias on dermoscopy. There is a 1cm red, waxy plaque at
the left elbow. Multiple telangiectasias on the cheeks.
Biopsy: Advanced Dermatology Associates, LTD (AD1505556, 05/18/2015) Left elbow, shave biopsy: “Mastocytoma.
‘By immunohistochemistry stain, there is a fairly dense band-like
population of CD117 positive, CD163 negative, and CD68 negative
cells that is somewhat obscured by a patchy lymphohistiocytic
infiltrate.”
Health Network Laboratories (9/8/2015, S15-28545, Bone
marrow, clot and biopsy left iliac crest): Systemic mastocytosis.
“The marrow findings meet criteria for systemic mastocytosis…
multifocal dense infiltrate of mast cells (>15 mast cells in
aggregates), scattered throughout the biopsy. The majority of mast
cells demonstrates spindle cell morphology. The mast cells express
CD25. No c-KIT mutation in exons 8,9,11,13 and 17 detected.”
Treatment: After a test spot was performed with no urticarial
response, multiple sessions of intense pulsed light at wavelength
570nm and fluence of 45.0 J/cm2 were performed to lesions on
the cheeks with improvement of telangiectatic lesions.
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Figure 2: Same patient after three treatments with IPL at
wavelength 570nm and fluence of 45.0 J/cm2.

Figure 3: (10x): On low power a lymphohistiocytic infiltrate can be observed.
On higher power the histiocyte-appearing cells are found to sometimes contain
subtle cytoplasmic granules.

Fig. 4 (10x)

Figure 4: (10x): Fairly dense band-like population of CD117+ mast cells
that is somewhat obscured by a patchy lymphohistiocytic infiltrate.

Discussion
Mastocytoses encompass a group of disorders that result from accumulation of abnormal mast cells in both the skin and other organs. Mastocytosis can present in both children and adults. The time
of development has prognostic implications in regard to systemic involvement. Childhood disease is typically limited to cutaneous lesions and includes maculopapular cutaneous mastocytosis (urticaria
pigmentosa), diffuse cutaneous mastocytosis or mastocytoma. These patients often have spontaneous resolution by puberty and rarely have life threatening anaphylaxis. Adults who present with new
cutaneous lesions are more likely to have systemic involvement, although an indolent disease course is the rule.
Serum tryptase levels often reflect the burden of neoplastic mast cells and help determine when bone marrow biopsy should be pursued to assess presence of systemic involvement. Criteria for diagnosis
of systemic mastocytosis include dense infiltrates of mast cells in bone marrow or other tissue (major) and atypical mast cell morphology, aberrant mast cell surface phenotype, serum/plasma tryptase
>20 ng/mL, codon 816 c-KIT mutation in peripheral blood, bone marrow, or lesional tissue (minor). Fulfillment of either one major and one minor criterion or three minor criteria is consistent with systemic
mastocytosis and should prompt workup to rule out an associated hematologic non-mast cell lineage disorder.
KIT is a type III receptor tyrosine kinase encoded by the proto-oncogene c-KIT that is expressed on mast cells. A subset of mastocytosis patients have alterations in KIT structure and activity leading to
constitutive activation of KIT and mast cell proliferation. Higher amounts of mast cell mediators released from abnormal mast cells cause the symptoms of mastocytosis. These mediators include those that
are preformed, newly formed and various cytokines. Symptoms are variable and include headaches, flushing, pruritus, gastrointestinal distress, dizziness, and bone pain.
Treatment of mastocytosis is aimed at symptom relief primarily with antihistamines. Cutaneous disease can be treated effectively with psoralen and ultraviolet A. Avoidance of mast cell degranulating
stimuli is important. Telangiectatic lesions have been successfully treated with modalities that target hemoglobin including pulsed dye laser and intense pulsed light. Intense pulsed light device is a noncoherent light source that delivers multiple wavelengths of visible and near-infrared light simultaneously. Filters are used to specify desired wavelengths that correspond with a target for treatment. When
treating patients with multiple telangiectasias, pretreatment with antihistamines should be used to ensure large scale mast cell degranulation does not occur with resultant anaphylaxis. This patient
represents a case of indolent systemic mastocytosis with diffuse telangiectasias that were improved dramatically with use of intense pulsed light. Long term follow up will be required to determine
whether these results are maintained or there is reappearance of the telangiectasias.
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